Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1250634 | 0.82 | — | — | |
| Formic Acid SCHEMBL31026672 | 0.76 | EGLN1 (0.30) | EGLN1 | |
| Trifluoroacetic Acid SCHEMBL28120081 | 0.75 | PKM (0.32) | EGLN1 | |
| Trifluoroacetic Acid SCHEMBL48017 | 0.71 | MAN1B1 (0.36) | SLC6A2SLC6A4SLC6A3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL28293433 | 0.70 | PKM (0.33) | — | |
| Trifluoroacetic Acid SCHEMBL28649474 | 0.69 | MAN1B1 (0.55) | SLC6A2SLC6A4SLC6A3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL28649473 | 0.69 | MAN1B1 (0.55) | SLC6A2SLC6A4SLC6A3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL30745983 | 0.68 | TSHR (0.32) | SLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL30746009 | 0.68 | TSHR (0.32) | SLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL28845085 | 0.68 | TSHR (0.32) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380309-A1 | CHOLINE METABOLISM INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-12-01 | — | — | US | disclosed |
| WO-2020117942-A1 | CHOLINE METABOLISM INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380309-A1 | CHOLINE METABOLISM INHIBITORS | CHKB, CRAT, HNMT | EGLN1 2040/4885SLC6A2 255/4885SLC6A4 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.